Conference Coverage (ASCO)

Imipenem/Cilastatin Has Nephroprotective Effect in BMT

Published in Blood Weekly, July 26th, 1999

Imipenem/cilastatin reduced the incidence of cyclosporin A-induced nephrotoxicity in bone marrow transplant recipients.

Panos S. Savvides and colleagues, Department of Clinical Care Research, New England Medical Center, Boston, Massachusetts, evaluated the nephroprotective effective of imipenem/cilastatin (I/C) undergoing bone marrow transplantation (BMT) while receiving continuous infusion cyclosporin A (CsA) to maintain a fixed whole blood level.

Savvides et al. reported their findings in a poster presentation at the 35th annual meeting of the American Society of Clinical Oncology (ASCO) May 15-18, 1999, held in Atlanta, Georgia ("Nephroprotective...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-07-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry